BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

399 related articles for article (PubMed ID: 21076461)

  • 1. β-Catenin pathway activation in breast cancer is associated with triple-negative phenotype but not with CTNNB1 mutation.
    Geyer FC; Lacroix-Triki M; Savage K; Arnedos M; Lambros MB; MacKay A; Natrajan R; Reis-Filho JS
    Mod Pathol; 2011 Feb; 24(2):209-31. PubMed ID: 21076461
    [TBL] [Abstract][Full Text] [Related]  

  • 2. β-catenin/Wnt signalling pathway in fibromatosis, metaplastic carcinomas and phyllodes tumours of the breast.
    Lacroix-Triki M; Geyer FC; Lambros MB; Savage K; Ellis IO; Lee AH; Reis-Filho JS
    Mod Pathol; 2010 Nov; 23(11):1438-48. PubMed ID: 20693983
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Nuclear β-catenin localization and mutation of the CTNNB1 gene: a context-dependent association.
    Kim G; Kurnit KC; Djordjevic B; Singh C; Munsell MF; Wang WL; Lazar AJ; Zhang W; Broaddus R
    Mod Pathol; 2018 Oct; 31(10):1553-1559. PubMed ID: 29795437
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinicopathological analysis of β-catenin and Axin-1 in solid pseudopapillary neoplasms of the pancreas.
    Huang SC; Ng KF; Yeh TS; Chang HC; Su CY; Chen TC
    Ann Surg Oncol; 2012 Jul; 19 Suppl 3():S438-46. PubMed ID: 21769465
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinicopathological features and prognostic significance of CTNNB1 mutation in low-grade, early-stage endometrial endometrioid carcinoma.
    Ruz-Caracuel I; López-Janeiro Á; Heredia-Soto V; Ramón-Patino JL; Yébenes L; Berjón A; Hernández A; Gallego A; Ruiz P; Redondo A; Peláez-García A; Mendiola M; Hardisson D
    Virchows Arch; 2021 Dec; 479(6):1167-1176. PubMed ID: 34420090
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Wnt/beta-catenin pathway activation is enriched in basal-like breast cancers and predicts poor outcome.
    Khramtsov AI; Khramtsova GF; Tretiakova M; Huo D; Olopade OI; Goss KH
    Am J Pathol; 2010 Jun; 176(6):2911-20. PubMed ID: 20395444
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Beta-catenin dysregulation in thyroid neoplasms: down-regulation, aberrant nuclear expression, and CTNNB1 exon 3 mutations are markers for aggressive tumor phenotypes and poor prognosis.
    Garcia-Rostan G; Camp RL; Herrero A; Carcangiu ML; Rimm DL; Tallini G
    Am J Pathol; 2001 Mar; 158(3):987-96. PubMed ID: 11238046
    [TBL] [Abstract][Full Text] [Related]  

  • 8. CTNNB1 Mutations and Aberrant β-Catenin Expression in Ovarian Endometrioid Carcinoma: Correlation With Patient Outcome.
    Zyla RE; Olkhov-Mitsel E; Amemiya Y; Bassiouny D; Seth A; Djordjevic B; Nofech-Mozes S; Parra-Herran C
    Am J Surg Pathol; 2021 Jan; 45(1):68-76. PubMed ID: 32769429
    [TBL] [Abstract][Full Text] [Related]  

  • 9. An oncogenic CTNNB1 mutation is predictive of post-operative recurrence-free survival in an EGFR-mutant lung adenocarcinoma.
    Kim Y; Ahn B; Yoon S; Lee G; Kim D; Chun SM; Kim HR; Jang SJ; Hwang HS
    PLoS One; 2023; 18(6):e0287256. PubMed ID: 37347751
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Wnt/β-catenin pathway activation in adrenocortical adenomas is frequently due to somatic CTNNB1-activating mutations, which are associated with larger and nonsecreting tumors: a study in cortisol-secreting and -nonsecreting tumors.
    Bonnet S; Gaujoux S; Launay P; Baudry C; Chokri I; Ragazzon B; Libé R; René-Corail F; Audebourg A; Vacher-Lavenu MC; Groussin L; Bertagna X; Dousset B; Bertherat J; Tissier F
    J Clin Endocrinol Metab; 2011 Feb; 96(2):E419-26. PubMed ID: 21084400
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Expression and significance of Wnt signaling components and their target genes in breast carcinoma.
    He Y; Liu Z; Qiao C; Xu M; Yu J; Li G
    Mol Med Rep; 2014 Jan; 9(1):137-43. PubMed ID: 24190141
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Wnt signaling pathway analysis in renal cell carcinoma in young patients.
    Bruder E; Moch H; Ehrlich D; Leuschner I; Harms D; Argani P; Briner J; Graf N; Selle B; Rufle A; Paulussen M; Koesters R
    Mod Pathol; 2007 Dec; 20(12):1217-29. PubMed ID: 17873895
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Genetic changes of Wnt pathway genes are common events in metaplastic carcinomas of the breast.
    Hayes MJ; Thomas D; Emmons A; Giordano TJ; Kleer CG
    Clin Cancer Res; 2008 Jul; 14(13):4038-44. PubMed ID: 18593979
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Recurrent Mutations in APC and CTNNB1 and Activated Wnt/β-catenin Signaling in Intraductal Papillary Neoplasms of the Bile Duct: A Whole Exome Sequencing Study.
    Fujikura K; Akita M; Ajiki T; Fukumoto T; Itoh T; Zen Y
    Am J Surg Pathol; 2018 Dec; 42(12):1674-1685. PubMed ID: 30212390
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Activation status of Wnt/ß-catenin signaling in normal and neoplastic breast tissues: relationship to HER2/neu expression in human and mouse.
    Khalil S; Tan GA; Giri DD; Zhou XK; Howe LR
    PLoS One; 2012; 7(3):e33421. PubMed ID: 22457761
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Epigenetic inactivation of the E-cadherin gene in eyelid sebaceous gland carcinoma.
    Jayaraj P; Sen S; Sharma A; Chosdol K; Kashyap S; Rai A; Pushker N; Bajaj MS; Ghose S
    Br J Dermatol; 2012 Sep; 167(3):583-90. PubMed ID: 22458737
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Wnt-beta-catenin pathway signals metastasis-associated tumor cell phenotypes in triple negative breast cancers.
    De P; Carlson JH; Wu H; Marcus A; Leyland-Jones B; Dey N
    Oncotarget; 2016 Jul; 7(28):43124-43149. PubMed ID: 27281609
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cytoplasmic localization of beta-catenin is a marker of poor outcome in breast cancer patients.
    López-Knowles E; Zardawi SJ; McNeil CM; Millar EK; Crea P; Musgrove EA; Sutherland RL; O'Toole SA
    Cancer Epidemiol Biomarkers Prev; 2010 Jan; 19(1):301-9. PubMed ID: 20056651
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Wnt/beta-catenin pathway deregulation in childhood adrenocortical tumors.
    Leal LF; Mermejo LM; Ramalho LZ; Martinelli CE; Yunes JA; Seidinger AL; Mastellaro MJ; Cardinalli IA; Brandalise SR; Moreira AC; Tone LG; Scrideli CA; Castro M; Antonini SR
    J Clin Endocrinol Metab; 2011 Oct; 96(10):3106-14. PubMed ID: 21849527
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Frequent inactivation of MCC/CTNNBIP1 and overexpression of phospho-beta-catenin(Y654) are associated with breast carcinoma: Clinical and prognostic significance.
    Mukherjee N; Dasgupta H; Bhattacharya R; Pal D; Roy R; Islam S; Alam N; Biswas J; Roy A; Roychoudhury S; Panda CK
    Biochim Biophys Acta; 2016 Sep; 1862(9):1472-84. PubMed ID: 27208794
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.